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T cell responses to asingle foreign protein antigen are generally specific for a few,
and often only one, of the peptides derived by processing of that antigen (1, 2) and
those determinants are referred to as immunodominant T cell epitopes . Though
the mechanisms underlying such restrictedT cell responses areunclear, severalhave
been suggested : (a) availability of an appropriate peptide after antigen processing
(1, 3), (b) the ability ofaparticular peptide to competewith otherpeptides forbinding
sites on the la molecule (3), and (c) the limitation of the expressedT cell repertoire
during thymic development (1, 2) .
We have explored in the present study theT cell response of H-2a mice to glyco-
protein D (gD), a coat protein of HSV, previously shown to confer a potent and
long-lived protective immune response (4-6) . Usinga set of28 overlapping synthetic
gD peptides, we have examined T cell response patterns in mice immunized with
recombinant gD-1 (a molecule lackingthe transmembrane and cytoplasmic regions
found in native gD-1) in CFA. Not unexpectedly, such T cells could be stimulated
by only one of these 28 peptides (peptide 13 : residues 241-260) . We have also exam-
ined T cell responses to rgD-1 and to the gD peptides when mice were infected with
HSV1 inPBS . To our surprise, the pattern ofresponsiveness wasradically different .
There appeared to be no immunodominance displayed since at least 17 peptides
(and up to 22 peptides) were found to be stimulatory . We believe these results call
into question the validity of the concept ofimmunodominant determinants when
considering immunity to infectious disease, and directly bear on issues of vaccine
design .
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Materials and Methods
Brief Definitive Report
Mice.
￿
B10.D2 mice were from TheJackson Laboratory (Bar Harbor, ME) and BALB/c
mice from Charles River Breeding Laboratories Inc. (Wilmington, MA) .
Antigens .
￿
rgD-1 was a generous gift from Dr. R. L . Burke (Chiron Corp., Emeryville,
CA)andmade as described elsewhere (7). Briefly, atruncatedgD gene ofHSV1, strain Patton,
was cloned inthe plasmidPHS118 andused to transfect Chinese hamster ovary(CHO) cells.
The rgD-1 is secreted asa glycosylated, 290amino acid longmoleculelacking 54 aminoacids at
theCOOH terminus andtransmembrane anchor domain . Immunoadsorbant-purified rgD-1
was used for immunization . A supernatant of transfectedCHO cells was used for in vitro
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FIGURE 1.
￿
Amino acid sequences of recombinant gD-1 and of its overlapping peptides.
T cell stimulation. Synthetic peptides were either purchased from Biosearch (San Rafael,
CA) or synthesized as described (6). All peptides are 20-mers and span the entire length of
rgD-1 with a set of peptides having 10 amino acid overlaps on either side (Fig. 1).
VirusPreparation.
￿
HSV1, strain (F), was provided by Dr. Nigel Fraser (The Wistar Insti-
tute). The virus was grown, and its titer was measured in BS-C-1 cells.
Lymph Node T Cell Proliferation Assay.
￿
Mice were immunized subcutaneously in the hind
footpads with 2.0 hg of rgD-1 in CFA or 5 x 105 PFU of HSV1 (F) in 20,ul of PBS. 7 d
later, cells from draining lymph nodes were treated with J11D + complement. T cells (2-
5 x 105) were cultured in 96-well microtiter plates with 1-3 x 105 X-irradiated (2,000 rad)
normal spleen cells with or without antigen. After 4 d, the degree of proliferation was deter-
mined as [3H]thymidine incorporation into DNA .
Antibody Blocking Experiments.
￿
Various concentrations of ascitic fluid or ammonium sul-
fate-precipitated culture supernatant of mAb MKD6 (anti-I-Ad) or 14-4-4S (anti-I-E) were
added at the initiation of culture. The percent inhibition was calculated as: 100 x (1 - ex-
perimental response/control response).
TCell Lines.
￿
B cell-depleted lymph node cells (5 x 106/ml) from HSVprimed mice were
cultured with X-irradiated syngeneic spleen cells (2,000 rad, 5 x 106/ml) plus antigen for
10 d. Viable cells (5 x 105/ml) were restimulated with antigen plus 5 x 106/ml of X-irradiated
(2,000 rad) splenocytes. Antigen specificity was analyzed after four cycles of stimulation.
Results and Discussion
Adult BALB/c and B10.D2 mice were immunized with rgD-1 in CFA and their
lymph node (LN) T cells were stimulated in vitro with the described set of overlap-
ping synthetic gD peptides (Fig. 2, A and B). T cells from both strains of mice
responded exclusively to peptide 13 (residues 241-260), which seems to be the only
immunodominant gD determinant in H-2d mice. The remaining peptides elicited
no significant responses. These findings are in accordance with the report ofChestnut
et al. (8) who found residues 245-260 to be the BALB/c immunodominant deter-
minant of gD.
To explore immunodominance in the context of a natural infection, we challenged
BALB/c mice subcutaneously with 5 x 105 PFU of HSV1 (F) in PBS in the hind
footpads. At this challenge dose ofvirus, none ofthe mice showed signs ofneurolog-
ical disease up to 2 mo after innoculation. The proliferative response of T cellsfrom
these HSVprimed animals either to HSV or to gD was at its peak around day 6-7
after viral innoculation and declined thereafter (datanot shown). 7 d after challenge,
the antigen specificity of these T cells was analyzed (Fig. 2 C).
Surprisingly, virus-primed LN T cells were found to respond not only to peptideFIGuRE 2.
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mice. T cells (5 x 105) were
cultured as described in A. Background incorporation was 1,800cpm. (D) A rgD-1-selected T cell line
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13 but also to the majority ofthe other peptides (i.e., a total of 17 of 28). Though
not shown, the response to gD was approximately one-third ofthe response to 106
PFU/mlofUVinactivated HSV (25,000cpm). While the responses to these 17 pep-
tides were reproducibly observed in all four experiments performed, occasional but
significant responses to otherpeptides, such as peptides 2, 4, 5, 8, and 11, were also
detected at least once.
Considering the fact that HSV carries many other antigens, it could be argued
that those T cells reactive to peptides other than peptide 13 are, in reality, specific
for other HSVrelated antigens that are crossreactive to the gD peptides used. An-
other explanation is that these peptide-reactive T cells are specific for gD and that
a viral challenge caused a response very different from that elicited by immuniza-
tion with a protein molecule in CFA.
To examine the gD specificity ofthose peptide-reactive Tcells, we stimulated in-
fectious virus-primed T cells with either rgD-1 or gD peptides to establish long-
term T cell lines. Fig. 2 D shows that a long-term, gD-selected line maintained al-
most the same antigen specificity pattern as that of the primary T cells (Fig. 2 C).
Furthermore, peptide-selected lines were shown to respond to rgD-1 as well as to
peptide (Table I). Thus, peptide-reactive T cells found in infectious virus-primed
LN T cells do contain gD-specific cells.
The fine specificity ofthepeptide-selected T cell lines was further dissected using
anti-Ia antibodies (Table II). Anti-I-Ad mAb, MKD6, blocked the responses ofpep-
tide 13- and 25-selected T cell lines to rgD-1, whereas anti-I-E mAb, 14-4-4S, did
not. Thus, these responses are completely I-A restricted. On the other hand, the
responsesofpeptide 17-and 18-selectedTcell lines torgD-1 were significantly blocked
byboth MKD6 (49 and 67%, respectively) and 14-4-4S (34 and 3117o, respectively),
indicating the existence of heterogeneous gD-specific T cell populations, ones that
are I-A restricted and others that are I-E restricted.1000
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TABLE I
The Proliferative Responses of HSV--primed Peptide-selected T Cell Lines
Proliferative activity* of T cell lines selected with:
No. 16
￿
No. 17
￿
No. 18
￿
No. 19
￿
No.21
￿
No. 24
￿
No. 25
￿
No. 12
￿
No. 13
Antigen 11-30 21-40 51-70 71-90 111-130 171-190 191-210 221-240 241-260
cpm x 10-3 t SD
Medium 1 .3 t
￿
1 .2 t
￿
2.8 t
￿
1 .6 t
￿
1 .7 t
￿
1.9 t
￿
2.1 t
￿
2.8 t
￿
4.0 t
0.2 0.3 0 .3 0.4 0 .4 0.6 0.9 0.4 0.8
Peptide
￿
4.8 t
￿
5.7 t
￿
9.0 t
￿
4.5 t
￿
9.8 t
￿
7.9 t
￿
8.7 f
￿
10.3 f
￿
18 .0 ±
0.6 0.8 0.7 0.8 1 .0 0.8 1 .0 0.9 1 .9
rgD-1
￿
5 .2 t
￿
5.9 t
￿
10.3 t
￿
5.3 t
￿
8.9 t
￿
8.3 t
￿
10 .5 f
￿
11 .6 t
￿
16.0 t
0.4 0.9 1 .0 0.9 1 .1 1 .4 1 .2 1 .3 1 .6
68-88t
￿
1 .4 t
￿
1 .4 t
￿
2.7 t
￿
1 .2 f
￿
1 .6 t
￿
2.1 t
￿
2.0 t
￿
2.6 f
￿
2 .9 t
0.5 0.1 0.8 0.3 0.3 0.9 0.3 0.6 0.3
* Peptide-selected BALB/c T cells (104) were cultured with 105 irradiated spleen cells with 2 ug/ml of gD
peptide, lug/ml of rgD-1, or 10 ug/ml of irrelevant peptide. Cells were incubated for 2.5 d. Results are
mean [3H]thymidine incorporation in cpm t SD for duplicate cultures.
t A synthetic peptide from guinea pig myelin basic protein (residues 68-88).
TABLE II
Anti-la Antibodies Block gD-sped Responses ofPeptide-selected T Cells
Proliferative activity*
No. 13 (241-260)
￿
No. 25 (191-21)
￿
No. 17 (31-50)
￿
No. 18 (51-70)
mAb Medt gD-1 Med gD-1 Med gD-1 Med gD-1
None
￿
1 .2 t
￿
15 .0 t
￿
1 .0 t
￿
10.4 t
￿
0.9 t
￿
6.6 t
￿
1 .0 t
￿
6.5 t
0.2 0.8 0.2 1 .0 0.0 0.8 0.0 0.1
Anti-IA 0.6 t
￿
4.5 t
￿
1 .2 t
￿
2.6 t
￿
1 .4 t
￿
4.2 t
￿
1 .3 t
￿
3.6 t
0.3
￿
0.6 (73)5
￿
0.1
￿
0.4(89)
￿
0.2
￿
0.5 (49)
￿
0.1
￿
0.1 (67)
Anti-IE 0.9 t
￿
14.1 t
￿
1 .6 t
￿
11 .1 t
￿
1 .0 f
￿
4.8 t
￿
1 .2 t
￿
5.0 t
0.1
￿
0.9 (5)
￿
0.3
￿
0.7 (-1)
￿
0.2
￿
0.3 (34)
￿
0.2
￿
0.1 (31)
* HSV-primed, petide-selected T cells (104) were cultured for 2.5 d with 105 irradiated spleno-
cytes with 1 Wg/ml of rgD-1 (gD-1). Anti-IA mAb, MKD6,and anti-IE mAb, 14-4-4S, were
added at the beginning ofculture at a final concentration of0.3 %. Theresults are duplicate
cultures with a mean [3H]thymidine incorporation.
t Med, medium control.
5 The numbers in the parentheses indicate the percent inhibition of the response.
Taken together, theseresultsindicate extensive diversity andacorresponding lack
of immunodominance in the T cell response to gD in H-2d mice when gD-specific
T cells are recruitedduring the acute phase of an HSV infection. There are several
possibilities that mightexplainthedifference betweengD-specific responseselicited
by infectious virus versus rgD in CFA. (a) There are structural differences between
viral gD and the recombinant gD used in these studies. A transmembrane and/or
a cytoplasmic portionof the gD molecule that is lacking in rgD-1 might be involved
in facilitating presentation of some ofthe "nonimmunodominant" gD determinants
in virus-primed animals. (b) There are potential differences in the in vivo concen-
tration ofgD. Although a 20-fold increase of achallengedose of rgD-1 did notrender
"nonimmunodominant"T cell populations detectable in a primaryproliferation assay
(datanot shown), the concentration of gD provided by immunization with CFAmay
not be as high as that achieved in a virus infection that does induce a full-range,YAMASHITA AND HEBER-KATZ
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gD-specificTcell response. (c) There is apossible difference in exogenous vs. endog-
enous antigen processing andpresentation. Some gD determinants might be more
efficientlypresented by virus-infected APCsas seen in the influenza neuraminidase
system (9). (d) There could be differences in the level of Ia expression on APCs.
Due to intense inflammatory responses elicited by viral infection, the level ofIa ex-
pression on APCs could be upregulated, rendering them more potent APCs (10).
(e) There may be quantitative differences in the APCs used in vivo. B cells are pro-
posed to function as APCs in clonal expansion ofT cells, especially in lymph nodes
(11). Inthe caseofaviralinfection, not only gD-specificB cellsbut also B cells specific
for any ofthe HSV antigens could function as APC to expand gD-specific T cells.
The factors mentioned above might operate alone or together in a positive fashion
to induce the T cell response seen during an acute HSV infection.
We were at first surprised that neither rgD-1 nor infectious virus induced a re-
sponse to the 1-20peptide sincewehad already shownthat the 1-23 peptidecoupled
to palmitic acid and incorporated into a liposome conferred potent long-term T
cell-mediated protection against alethal HSV challenge (6). However, we notethat
depletion of CD8+ cells could eliminate adoptive transfer of protection while the
response measured in the present study is mediated by CD4+ T cells (data not
shown). Furthermore, the protection-conferring determinant on the 1-23 construct
lies near the COOH terminus as an 8-23 construct protects and a 1-16 construct
does not (Yamashita, K., and E. Heber-Katz, manuscript in preparation). Also, the
fact that the 11-30 peptide (No. 16) was stimulatory after priming with infectious
virus supports the importance ofthis COON-terminal region. Finally, these studies
emphasizethat immunization protocols involving infectious virusversus rgDin CFA
versus peptide-lipid-liposome constructs in CFA are not equivalent in the qualita-
tive nature of the immunity induced and bear on issues of vaccine design.
Extensive diversity in T cell responses has been previously seen with influenza
hemagglutinin (12, 13). That the Tcells analyzed were derived from virus-infected
animalsin both ofthese studies, plus ourown, suggests thatTcell response patterns
observed when animals are immunized with a purified protein in adjuvant do not
necessarily reflect the maximum immune potential of an animal. Though T cell
immunodominance hasbeendemonstrated, even in thecaseofviral infections (here
CD8+ T cells were examined; reference 14), the resultspresented here raise the issue
of T cell immunodominance generally as a biologically meaningful concept.
Summary
Glycoprotein D(gD) ofHSV hasbeen shown to bea potent immunogen. To ana-
lyzethe T cell antigenic determinants on gD, aseries of28 overlapping20-mer pep-
tides that span the extracellular portion of gD-1 were examined for their ability to
stimulate T cells from rgD-1 orinfectious HSV1-primed H-2d mice in vitro. rgD-
1-primedcells responded exclusivelyto peptide 241-260, theimmunodominant de-
terminant of gD in H-2d mice. In contrast, infectious HSV-primed T cells were
shown to respond to 17 (and up to 22) of 28 synthetic gD peptides. These results
indicate an extensive diversity in the T cell repertoire to gD in H-2d mice with T
cells directed to a broad array of peptide determinants being recruited during the
acute phase of an HSV infection.1002
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